CXCR5 engineered human and murine Tregs for targeted suppression in secondary and tertiary lymphoid organs is a research paper published in Frontiers in Immunology (2025). On theSindex it has a DataRank of 0.241. It has been cited 4 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.241
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Heart, Lung, and Blood Institute
Grant: R21HL170146
National Institute of Allergy and Infectious Diseases
Grant: R56AI175187
National Institutes of Health
Grant: 1R56AI175187-01A1
Optimizing precision Treg therapy to control anti-drug antibodies
National Institutes of Health
Grant: 3P30CA082709-16S3
Indiana University Melvin and Bren Simon Cancer Center Support Grant
National Institutes of Health
Grant: 5R21HL170146-02
Development of a cellular therapy product with single specificity and improved persistence to prevent immunity to biotherapeutics
FWCI
1.78
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals